製品番号: HY-B1135

ベンゾブロマロン

(別名: Benzbromarone)

10 Cited Publications

カスタマーレビュー

Based on 10 publication(s) in Google Scholar

Benzbromarone is an orally active anti-gout agent. Benzbromarone has anti-infammatory, anti-oxidative stress and nephroprotective effects. Benzbromarone can be used for the research of hyperuricemia and gout.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.91%
CAS 番号: 3562-84-3
分子式: C₁₇H₁₂Br₂O₃
分子量:424.08

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Benzbromarone 構造式

CAS 番号: 3562-84-3

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (10)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

IL-1β

IL-8

Caspase-8

Caspase 9

Caspase 3

Bcl-2

Interleukin Related アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

Bcl-2 Family アイソフォーム固有の製品をすべて表示 :

NF-κB アイソフォーム固有の製品をすべて表示 :

JNK アイソフォーム固有の製品をすべて表示 :

HSP アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	0.3 μM Compound: benzbromarone	Inhibition of human URAT1-mediated urate uptake in HEK293 cells Inhibition of human URAT1-mediated urate uptake in HEK293 cells	[PMID: 17325024]
HEK-293T	IC₅₀	0.12 μM Compound: 2	Inhibition of human URAT1 expressed in HEK293T cells assessed as reduction in [14C]uric acid uptake measured after 5 mins by liquid scintillation counting method Inhibition of human URAT1 expressed in HEK293T cells assessed as reduction in [14C]uric acid uptake measured after 5 mins by liquid scintillation counting method	[PMID: 28351592]
MDCK	IC₅₀	35 nM Compound: 7, benzbromarone	Inhibition of human URAT1 expressed in human MDCK cells Inhibition of human URAT1 expressed in human MDCK cells	[PMID: 21449597]
MDCK	EC₅₀	39 μM Compound: 3	Antiviral activity against Influenza A virus (A/PR/8/34) (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 48 hrs by plaque reduction assay Antiviral activity against Influenza A virus (A/PR/8/34) (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 48 hrs by plaque reduction assay	[PMID: 25856229]
MDCK	EC₅₀	39 μM Compound: 21	Antiviral activity against Influenza A virus A/PR/8/34 (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 2 days by plaque reduction assay Antiviral activity against Influenza A virus A/PR/8/34 (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 2 days by plaque reduction assay	[PMID: 27046062]
RPTEC	IC₅₀	6.8 μM Compound: BBR	Inhibition of uric acid uptake in human RPTEC Inhibition of uric acid uptake in human RPTEC	[PMID: 33684442]
S2	IC₅₀	4.6 μM Compound: Benzbromarone	TP_TRANSPORTER: inhibition of Urate uptake (Urate: 300 uM) in OAT1-expressing S2 cells TP_TRANSPORTER: inhibition of Urate uptake (Urate: 300 uM) in OAT1-expressing S2 cells	[PMID: 12472777]
Sf9	IC₅₀	4 μM Compound: Benzbromarone	Inhibition of human MRP1 expressed in Spodoptera frugiperda Sf9 cells assessed as inhibition of NEM-GS-induced vanadate-sensitive ATPase activity measured by generation of inorganic phosphate by spectrophotometry in presence of glutathione Inhibition of human MRP1 expressed in Spodoptera frugiperda Sf9 cells assessed as inhibition of NEM-GS-induced vanadate-sensitive ATPase activity measured by generation of inorganic phosphate by spectrophotometry in presence of glutathione	[PMID: 21530277]
Sf9	IC₅₀	4 μM Compound: Benzbromarone	Inhibition of Homo sapiens (human) MRP1 expressed in Sf9 cell membranes assessed as decrease in N-ethyl-maleimide-glutathione-induced inorganic phosphate production by spectrophotometric analysis in presence of glutathione Inhibition of Homo sapiens (human) MRP1 expressed in Sf9 cell membranes assessed as decrease in N-ethyl-maleimide-glutathione-induced inorganic phosphate production by spectrophotometric analysis in presence of glutathione	10.1007/s00044-012-9994-0
Vero	IC₅₀	31.83 μg/mL Compound: Benzbromarone	Cytotoxicity against african green monkey Vero cells measured after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells measured after 48 hrs by MTT assay	[PMID: 38547733]

体外実験

Benzbromarone (5-20 μM, 24 h) protects against propofol (HY-B0649)‑induced cytotoxicity in Human brain microvascular endothelial cells (HBMVECs)^[1].
Benzbromarone (5-20 μM, 24 h) mitigates propofol (HY-B0649)‑induced oxidative stress and inhibits expression of pro‑inflammatory cytokines and Chemokines in HBMVECs^[1].
Benzbromarone (1-100 μM, 2-24 h) activats the NRF2 signaling pathway in HepG2 cells^[2].
Benzbromarone (1-30 μM, 24 h) promotes degradation of HSP47 to ameliorate collagen overproduction in human keloid fibroblasts^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

HBMVECs
Concentration:

5 μM, 10 μM, 20 μM
Incubation Time:

24 h
Result:

Improved the viability reduced by propofol.

Western Blot Analysis^[2]

Cell Line:

HepG2 cells
Concentration:

1 μM, 2 μM, 5 μM, 10 μM, 20 μM, 50 μM, 100 μM
Incubation Time:

2 h, 6 h, 24 h
Result:

Increased NRF2 protein expression in HepG2 cells exposed for 2 h, 6 h and 24 h at any concentration.
Significantly accumulated the protein of NRF2 in the nuclear fraction after exposure to 100 μM at any time point.
Caused an increase in the protein expression of TRX1 and TRX2.
Significantly increased the ratio of oxidized TRX2 to reduced TRX2 at a concentration of 100 μM.

体内実験

Benzbromarone (25-50 mg/kg, Intragastric, once a day for four weeks) aggravates hepatic steatosis in high fat diet (HFD)-induced obese (DIO) mice^[3].
Benzbromarone (10 mg/kg, Oral gavage, once a day for 14 consecutive days) attenuates the nephrotoxicity caused by cisplatin(HY-17394) in cisplatin treated rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

High fat diet (HFD)-induced obese (DIO) mice^[3]
Dosage:

25 mg/kg, 50 mg/kg
Administration:

Intragastric (i.g.)
Result:

Aggravated lipid accumulation in the liver of DIO mice.
Significantly increased triglyceride accumulation and AST, ALT levels.
Regulated multiple lipid metabolism genes and the expression of protein markers associated with apoptosis, endoplasmic reticulum stress, and inflammation in the liver of DIO mice.

Animal Model:

Cisplatin treated rats^[2]
Dosage:

10 mg/kg
Administration:

Oral gavage (p.o.)
Result:

Ameliorated the elevation in serum creatinine and blood urea nitrogen (BUN) levels induced by cisplatin.
Counteracted oxidative stress induced by cisplatin and enhances anti-oxidant defenses in kidney.
Alleviated the inflammatory events of nephrotoxicity induced by cisplatin.
Attenuated cisplatin-induced apoptosis.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 3562-84-3
性状 Solid
分子量 424.08
分子式 C₁₇H₁₂Br₂O₃
Color White to off-white
SMILES

O=C(C1=CC(Br)=C(O)C(Br)=C1)C2=C(CC)OC3=CC=CC=C23
別名

Benzbromarone
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (10)

All Cell Proliferation/Viability AssayBio/Physico-chemical AssayIn Vivo Efficacy StudyWB

Sort by:

Journal Impact Factor

Nat Commun

Molecular mechanism of drug inhibition of URAT1. [Abstract]

2025 Jul 16;16(1):6551. PMID: 40670375
Acta Pharm Sin B

Generation and applications of an expandable and mature hiPSC-derived liver organoid. [Abstract]

2025 Dec;15(12):6382-6398. PMID: 41477334

Benzbromarone purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]

Inhibition of ¹⁴C-urate transport by Benzbromarone in URAT1^EM and its mutants.
Adv Sci (Weinh)

Slow Metabolism-Driven Amplification of Hepatic PPARγ Agonism Mediates Benzbromarone-Induced Obesity-Specific Liver Injury. [Abstract]

2024 Nov 29:e2409126. PMID: 39611414
Adv Sci (Weinh)

ANO1-Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer-Associated Fibroblasts. [Abstract]

2023 Aug;10(24):e2300881. PMID: 37341301

Benzbromarone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Aug;10(24):e2300881. [Abstract]

Benzbromarone (BBR) (1-100 μM; 72 h) inhibited in vitro proliferation of multiple human GC and CRC cell lines.

Benzbromarone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Aug;10(24):e2300881. [Abstract]

Benzbromarone (BBR) (50 mg/kg; p.o.; once every other day for 3 weeks) showed anti-tumor effectiveness in ANO1-positive GC PDX mice.

Benzbromarone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Aug;10(24):e2300881. [Abstract]

Benzbromarone (BBR) (50 mg/kg; p.o.; once every other day for 3 weeks) evidently augmented the anti-tumor effect of anti-PD-1 antibody against MC38/CT26 xenograft mice.

Benzbromarone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Aug;10(24):e2300881. [Abstract]

Benzbromarone (BBR) (1-100 μM) dose-dependently inhibited ANO1's protein expression in multiple GI cancer cells.
Phytother Res

α-Mangostin Attenuates Blood Pressure and Reverses Vascular Remodeling by Balancing ACE/AT1R and ACE2/Ang-(1-7)/MasR Axes in Ang II-Infused Hypertensive Mice. [Abstract]

2024 Dec;38(12):5918-5929. PMID: 39410864
Stem Cell Res Ther

Co-transplantation with adipose-derived cells to improve parathyroid transplantation in a mice model. [Abstract]

2020 May 26;11(1):200. PMID: 32456711
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Int Immunopharmacol

METTL14 downregulates GLUT9 through m6A methylation and attenuates hyperuricemia-induced fibrosis in mouse renal tubular epithelial cells. [Abstract]

2024 Oct 10;143(Pt 1):113308. PMID: 39393275
Biotechnol Bioeng

An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]

2021 Dec;118(12):4687-4698. PMID: 34478150
bioRxiv

2026 Apr 30.

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (235.80 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3580 mL

11.7902 mL

23.5805 mL

5 mM

0.4716 mL

2.3580 mL

4.7161 mL

10 mM

0.2358 mL

1.1790 mL

2.3580 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (4.90 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 2.5 mg/mL (5.90 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (288 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Huang Z, et al. The protective effects of benzbromarone against propofol-induced inflammation and injury in human brain microvascular endothelial cells (HBMVECs) [J]. Neurotoxicity Research, 2021, 39(5): 1449-1458. [Content Brief]

[2]. Roos N J, et al. The uricosuric benzbromarone disturbs the mitochondrial redox homeostasis and activates the NRF2 signaling pathway in HepG2 cells [J]. Free Radical Biology and Medicine, 2020, 152: 216-226. [Content Brief]

[3]. Park J G, et al. Benzbromarone Induces Targeted Degradation of HSP47 Protein and Improves Hypertrophic Scar Formation [J]. Journal of Investigative Dermatology, 2023. [Content Brief]

[4]. Sun P, et al. Benzbromarone aggravates hepatic steatosis in obese individuals [J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2018, 1864(6): 2067-2077. [Content Brief]

[5]. Abdel-Razek E A N, et al. Benzbromarone mitigates cisplatin nephrotoxicity involving enhanced peroxisome proliferator-activated receptor-alpha (PPAR-α) expression [J]. Life sciences, 2020, 243: 117272. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3580 mL	11.7902 mL	23.5805 mL	58.9511 mL
	5 mM	0.4716 mL	2.3580 mL	4.7161 mL	11.7902 mL
	10 mM	0.2358 mL	1.1790 mL	2.3580 mL	5.8951 mL
	15 mM	0.1572 mL	0.7860 mL	1.5720 mL	3.9301 mL
	20 mM	0.1179 mL	0.5895 mL	1.1790 mL	2.9476 mL
	25 mM	0.0943 mL	0.4716 mL	0.9432 mL	2.3580 mL
	30 mM	0.0786 mL	0.3930 mL	0.7860 mL	1.9650 mL
	40 mM	0.0590 mL	0.2948 mL	0.5895 mL	1.4738 mL
	50 mM	0.0472 mL	0.2358 mL	0.4716 mL	1.1790 mL
	60 mM	0.0393 mL	0.1965 mL	0.3930 mL	0.9825 mL
	80 mM	0.0295 mL	0.1474 mL	0.2948 mL	0.7369 mL
	100 mM	0.0236 mL	0.1179 mL	0.2358 mL	0.5895 mL

Keywords

Benzbromarone

10 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ベンゾブロマロン

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Rare Diseases Drug Library

Human Metabolite Library

Pain-Related Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 Benzbromarone

Interleukin Related アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

Bcl-2 Family アイソフォーム固有の製品をすべて表示

NF-κB アイソフォーム固有の製品をすべて表示

JNK アイソフォーム固有の製品をすべて表示

HSP アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (10)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Benzbromarone 関連分類

HY-B1135 関連分類